December 20, 2024

Empagliflozin Reduces Risk of Diabetic Retinopathy Progression

Investigators found a 22% reduced risk of progression in patients with preexisting NPDR.

Conexiant

December 20, 2024

Workplace Discrimination in Ophthalmology

“Your husband also works, so you’re the second income.’”

Conexiant

December 16, 2024

FDA 6-Month Drug Pipeline

A pipeline of novel drugs awaits FDA review through the first half of 2025.

Conexiant

December 13, 2024

Obstructive Sleep Apnea Affects nAMD

The potential overnight reduction of the critical oxygen supply could present a retinal health risk.

Conexiant

December 13, 2024

Faricimab Shows Better Anatomic Outcomes Compared to Aflibercept for nAMD

New data from TENAYA and LUCERNE supports “the vascular stabilizing effects of Ang-2 inhibition beyond anti-VEGF-A alone.”

Conexiant

December 10, 2024

Foveal Avascular Zone Area: A New Endpoint for Macular Capillary Nonperfusion Trials?

A subset of patients may still lose vision after PRP for diabetic retinopathy, but FAZ enlargement may be a sensitive measure for monitoring diabetic macular ischemia.

Conexiant

December 05, 2024

Vision Deficits Associated with Mild Traumatic Brain Injury

A comprehensive battery of metrics and tests is the most effective at detecting TBI-related vision problems than single metrics alone.

Conexiant

December 03, 2024

Novel Eye Perfusion Model Advances Retinal Disease Research

Innovative perfusion techniques recreate physiological conditions in the retina, offering a powerful tool for studying blindness and eye diseases.

Conexiant

December 02, 2024

Myopia Interventions Ranked by Efficacy

Interventions in childhood, “have the potential to reduce future visual impairment."

Conexiant